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Maternal inﬂ uenza immunisation in resource-limited settings
Pregnant women and young infants are at high risk 
of developing severe inﬂ uenza.1,2 Among infants, 
those younger than 6 months have the highest risk of 
developing complications associated with inﬂ uenza;3 
however, antiviral treatments and inﬂ uenza vaccines 
are not approved in this age group. Given that inﬂ uenza 
vaccines administered to pregnant women have 
shown a good safety proﬁ le4 and eﬃ  cacy to prevent 
inﬂ uenza in infants younger than 6 months,5,6 maternal 
immunisation seems to be an important strategy to 
protect both pregnant women and their infants. WHO 
targets seasonal inﬂ uenza vaccination of pregnant 
women as a high priority.7 Most high-income countries 
recommend maternal inﬂ uenza immunisation to reduce 
the burden of inﬂ uenza in the pregnant woman and her 
infant.8 However, additional data are needed to support 
decisions about introduction of inﬂ uenza vaccine in 
pregnant women in resource-limited settings. The Bill 
& Melinda Gates Foundation funded three large trials 
in South Africa, Mali, and Nepal, with the objective of 
increasing the evidence base for the eﬀ ect of maternal 
inﬂ uenza immunisation.9 
In The Lancet Infectious Diseases, Milagritos D Tapias 
and colleagues10 report results of the trial done in 
Mali—a poorly-resourced country with high infant 
and maternal mortality. This is the largest randomised 
controlled trial evaluating the eﬃ  cacy, safety, and 
immuno genicity of trivalent inactivated inﬂ uenza 
vaccine administered to third-trimester pregnant 
women to prevent inﬂ uenza in infants younger than 
6 months. 4193 women were immunised: 2018 with 
tri valent inactivated inﬂ uenza vaccine and 2085 with 
conjugate quadrivalent meningococcal vaccine. Vaccine 
eﬃ  cacy against ﬁ rst-episode laboratory conﬁ rmed 
inﬂ uenza in infants (the primary outcome) was 33·1% 
(95% CI 3·7–53·9) in infants born to women immunised 
at any time prepartum (intention-to-treat analysis), and 
37·3% (7·6–57·8) in those born to women vaccinated 
at least 14 days prepartum (per-protocol analysis). 
Among participating women, vaccine eﬃ  cacy was 
70·3% (95% CI 42·2–85·8) overall, 76·6% (28·4–94·3) 
in pregnant women, and 70·1% (28·0–89·1) in the post-
partum period. There was no beneﬁ cial eﬀ ect of the 
trivalent inactivated inﬂ uenza vaccine on birthweight. 
The technical and logistical feasibility of implementation 
of a new maternal immunisation programme was also 
shown with a high rate of recruitment among eligible 
women.
Evidence of the eﬃ  cacy of maternal inﬂ uenza 
immunisation to prevent inﬂ uenza in infants in low-
income countries from this trial is convincing and 
in agreement with ﬁ ndings from the two previously 
reported randomised trials from Bangladesh (63% 
vaccine eﬃ  cacy, 95% CI 5–85)5 and South Africa (48·8%, 
11·6–70·4).6
However, important questions follow. First, is the 
health impact of maternal inﬂ uenza immunisation 
(on pregnant women, fetuses, and neonates) and 
countries’ demands enough to justify support from 
international agencies (eg, GAVI, the Vaccine Alliance) 
and others? Maternal inﬂ uenza immunisation could 
avert around 45 deaths per 100 000 people vaccinated 
in GAVI-eligible countries—ie, about 210 000 mother–
infant deaths from 2015 to 2030 with broad adoption 
across GAVI countries.11 However, these ﬁ gures are 
estimates, and more speciﬁ c data for inﬂ uenza burden 
in poor-income countries are needed to better estimate 
health impact and convince decision makers. Second, 
is maternal inﬂ uenza immunisation acceptable for 
pregnant women and health providers? In high-income 
countries, inﬂ uenza vaccine coverage is less than 50%, 
even during the 2009 H1N1 pandemic.12,13 However, in 
resource-limited countries, routine administration of 
tetanus toxoid vaccine as an important part of antenatal 
care should facilitate both implementation and 
acceptability of inﬂ uenza vaccine from pregnant women 
and health workers. The third question is regarding 
the feasibility of seasonal vaccine supply, surveillance, 
and strain-matching? Logistical challenges with 
supplying, stocking, and administration of seasonal 
vaccines should be overcome to achieve high coverage 
of maternal immunisation. Development of maternal 
immunisation platforms in low-income countries seems 
to be an appealing approach. 
The results of Tapia and colleagues’ large randomised 
trial are important because they show not only the 
eﬃ  cacy, but also the feasibility, of maternal seasonal 
inﬂ uenza immunisation on infant protection during the 
ﬁ rst months of life in Mali. Moreover, the investigators 
put forward several propositions to overcome the 
Lancet Infect Dis 2016
Published Online
May 31, 2016
http://dx.doi.org/10.1016/
S1473-3099(16)30121-9
See Online/Articles
http://dx.doi.org/10.1016/
S1473-3099(16)30054-8
M
ar
tin
 V
og
l/A
P/
Pr
es
s A
ss
oc
ia
tio
n 
Im
ag
es
 
Comment
2 www.thelancet.com/infection   Published online May 31, 2016   http://dx.doi.org/10.1016/S1473-3099(16)30121-9
4 Loubet P, Kerneis S, Anselem O, Tsatsaris V, Goﬃ  net F, Launay O. 
Should expectant mothers be vaccinated against ﬂ u? A safety review. 
Expert Opin Drug Saf 2014; 13: 1709–20.
5 Zaman K, Roy E, Arifeen SE, et al. Eﬀ ectiveness of maternal inﬂ uenza 
immunization in mothers and infants. N Engl J Med 2008; 359: 1555–64.
6 Madhi SA, Cutland CL, Kuwanda L, et al. Inﬂ uenza vaccination of pregnant 
women and protection of their infants. N Engl J Med 2014; 371: 918–31.
7 WHO. Vaccines against inﬂ uenza WHO position paper-November 2012. 
Wkly Epidemiol Rec 2012; 87: 461–76.
8 Mak TK, Mangtani P, Leese J, et al. Inﬂ uenza vaccination in pregnancy: 
current evidence and selected national policies. Lancet Infect Dis 2008; 
8: 44–52.
9 Omer SB, Richards JL, Madhi SA, et al. Three randomized trials of maternal 
inﬂ uenza immunization in Mali, Nepal, and South Africa: Methods and 
expectations. Vaccine 2015; 33: 3801–12. 
10 Tapia MD, Sow SO, Tamboura B, et al. Maternal immunisation with 
trivalent inactivated inﬂ uenza vaccine for prevention of inﬂ uenza in infants 
in Mali: a prospective, active-controlled, observer-blind, randomised 
phase 4 trial. Lancet Infect Dis 2016; published online May 31. 
http://dx.doi.org/10.1016/S1473-3099(16)30054-8.
11 GAVI, the Vaccine Alliance. Inﬂ uenza vaccine investment strategy. 2013. 
http://www.gavi.org/about/strategy/vaccine-investment-strategy/ 
(accessed May 13, 2016).
12 Blondel B, Mahjoub N, Drewniak N, Launay O, Goﬃ  net F. Failure of the 
vaccination campaign against A(H1N1) inﬂ uenza in pregnant women in 
France: results from a national survey. Vaccine 2012; 30: 5661–65.
13 Wiley KE, Leask J. Respiratory vaccine uptake during pregnancy. 
Lancet Respir Med 2013; 1: 9–11.
diﬃ  culties of seasonal inﬂ uenza vaccination in resource-
limited countries. Nevertheless, supplementary data for 
inﬂ uenza disease burden in low-income countries are 
urgently needed to support GAVI’s decision. 
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